InsiderSignal.AI

InsiderSignal.ai

BCAX - Bicara Therapeutics Inc.

Insider Sale by Cohlhepp Ryan (Pres, COO)

1 Month
After Trade
Before Trade

Loading data...

Trade Summary

Yesterday, Cohlhepp Ryan, serving as Pres, COO at Bicara Therapeutics Inc. (BCAX), sold 12,500 shares at $19.66 per share, for a total transaction value of $245,714.00. Following this transaction, Cohlhepp Ryan now holds 200,641 shares of BCAX.

This sale represents a 6.00% decrease in Cohlhepp Ryan's stake in the company. This is considered a high-conviction trade given the significant change in ownership.

The trade was executed on Monday, March 16, 2026 and publicly disclosed via SEC Form 4 filing on Tuesday, March 17, 2026, 1 day after the trade was made.

Bicara Therapeutics Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.

Cohlhepp Ryan

Cohlhepp Ryan

Pres, COO

Ryan Cohlhepp, Pharm.D., is the President and Chief Operating Officer of Bicara Therapeutics Inc. (BCAX), a role he has held since October 2020, and also serves as a Class I director.[[1]](https://fintool.com/app/research/companies/BCAX/people/ryan-cohlhepp)[[5]](https://www.bicara.com/team/ryan-cohlhepp/) At 48 years old, he has over 20 years of experience in the life sciences industry, previously serving as Senior Vice President of R&D Strategy and Operations at Rheos Medicines from March 2018 to October 2020, where he led R&D strategy and operations.[[1]](https://fintool.com/app/research/companies/BCAX/people/ryan-cohlhepp)[[5]](https://www.bicara.com/team/ryan-cohlhepp/) Dr. Cohlhepp has been instrumental in scaling Bicara's R&D and operations around its lead program, ficerafusp alfa, and navigating the company's IPO transition.[[1]](https://fintool.com/app/research/companies/BCAX/people/ryan-cohlhepp) He owns 580,757 shares (1.1% of outstanding as of April 14, 2025) and has engaged in recent insider trading, including buying and selling shares in December 2025 and selling shares in early 2026 under Rule 10b5-1 plans.[[1]](https://fintool.com/app/research/companies/BCAX/people/ryan-cohlhepp)[[2]](https://www.ainvest.com/news/bicara-therapeutics-coo-cohlhepp-ryan-buys-sells-shares-december-2025-2512/)[[4]](https://www.investing.com/news/insider-trading-news/cohlhepp-bicara-therapeutics-president-sells-315k-in-shares-93CH-4545834)[[6]](https://www.stocktitan.net/sec-filings/BCAX/form-4-bicara-therapeutics-inc-insider-trading-activity-af3e47ebe4e0.html) His compensation includes a 2024 base salary of $517,500 (post-IPO rate $560,000) and a target annual bonus of 50% of base.[[1]](https://fintool.com/app/research/companies/BCAX/people/ryan-cohlhepp)

View full insider profile →

Trade Price

$19.66

Quantity

12,500

Total Value

$245,714.00

Shares Owned

200,641

Trade Date

Monday, March 16, 2026

1 days ago

SEC Filing Date

Tuesday, March 17, 2026

Filed 1 day after trade

HEALTHCAREBIOTECHNOLOGY

About Bicara Therapeutics Inc.

Company Overview

No company information available
View news mentioning BCAX

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/4869054

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime